Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 11:13 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2113–2136 of 16,851 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Symptom Clusters Clear all

Conditions: HIV Infections
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 180 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2000 – 2008
U.S. locations: 1
States / cities: Cambridge, Massachusetts

Conditions: Obstructive Sleep Apnea
Interventions: Genio™ system; Device
Lead sponsor: Nyxoah S.A.; Industry
Eligibility: 22 Years to 75 Years
Enrollment: 115 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 16
States / cities: Birmingham, Alabama • Boca Raton, Florida • Tampa, Florida + 12 more

Conditions: Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
Interventions: anti-thymocyte globulin, sargramostim, busulfan, etoposide, fludarabine phosphate, prednisone, tacrolimus, allogeneic hematopoietic stem cell transplantation, umbilical cord blood transplantation; Biological · Drug · Procedure
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 55 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2009
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Pleuropulmonary Blastoma, Cystic Nephroma, Ovarian Sertoli-Leydig Cell Tumors, Ocular Medulloepithelioma, Nasal Chondromesenchymal Hamartoma
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 1 Month to 99 Years
Enrollment: 1,500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2011
U.S. locations: 2
States / cities: Bethesda, Maryland • Rockville, Maryland

Conditions: Long QT Syndrome (LQTS) 2
Interventions: baseline lead-in, THRV-1268; Other · Drug
Lead sponsor: Thryv Therapeutics, Inc.; Industry
Eligibility: 15 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 9
States / cities: Scottsdale, Arizona • San Francisco, California • Chicago, Illinois + 6 more

Conditions: Interstitial Cystitis, Mindfulness, Complementary Medicine, Painful Bladder Syndrome
Interventions: Mindfulness-based Stress Reduction (MBSR), Usual medical therapy; Other
Lead sponsor: University of New Mexico; Other
Eligibility: 18 Years and older · Female only
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: HIV Infections
Interventions: rAd35 Env A, rAd5 Env A, rAd5 Env B; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 180 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2016
U.S. locations: 8
States / cities: Birmingham, Alabama • San Francisco, California • Decatur, Georgia + 4 more

Conditions: Kinky Hair Syndrome
Interventions: Copper Histidine; Drug
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: Not listed
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1990 – 2013
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: HIV Disease, Herpes Simplex 1, Herpes Simplex 2
Interventions: Blood draw; Other
Lead sponsor: Global Research Institute; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Hypogammaglobulinemia, Autoimmune Conditions, Rheumatic Conditions, Infections
Interventions: Panzyga, 10% Intravenous Solution, Placebo; Drug · Other
Lead sponsor: Octapharma; Industry
Eligibility: 18 Years and older
Enrollment: 360 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 8
States / cities: Glendale, Arizona • Mesa, Arizona • Scottsdale, Arizona + 5 more

Conditions: Long QT Syndrome
Interventions: Not listed
Lead sponsor: Pediatrix; Other
Eligibility: Up to 20 Years
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Cardiovascular Diseases, Heart Diseases, HIV Infections, Hyperlipidemia, Hypertriglyceridemia, Insulin Resistance, Atherosclerosis
Interventions: Diet, Exercise, Niacin, Fenofibrate, Placebos; Behavioral · Drug · Other
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years to 65 Years
Enrollment: 221 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2012
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Hematopoietic and Lymphoid Cell Neoplasm, High Risk Acute Myeloid Leukemia, High Risk Myelodysplastic Syndrome, Lymphoproliferative Disorder, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasm, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent High Risk Myelodysplastic Syndrome, Recurrent Hodgkin Lymphoma, Recurrent Myelodysplastic Syndrome, Recurrent Non-Hodgkin Lymphoma, Recurrent Plasma Cell Myeloma
Interventions: Allogeneic Hematopoietic Stem Cell Transplantation, Busulfan, Cyclophosphamide, Fludarabine, Fludarabine Phosphate, Laboratory Biomarker Analysis, Mycophenolate Mofetil, Pharmacological Study, Tacrolimus, Thiotepa; Procedure · Drug · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 12 Years to 75 Years
Enrollment: 204 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Myasthenic Syndromes, Congenital
Interventions: 3,4-diaminopyridine; Drug
Lead sponsor: Vern C. Juel, M.D.; Other
Eligibility: Not listed
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: E.Coli Infections, Bloodstream Infection
Interventions: SNIPR001, Placebo; Drug
Lead sponsor: SNIPR Biome Aps.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Leukemia, Lymphoma
Interventions: LMB-2 immunotoxin; Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Up to 21 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 5
States / cities: Atlanta, Georgia • Baltimore, Maryland • Bethesda, Maryland + 2 more

Conditions: Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome
Interventions: Not listed
Lead sponsor: Kiadis Pharma; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 178 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Autism Spectrum Disorders
Interventions: Not listed
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 18 Months and older
Enrollment: 1,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2030
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Prion Disease
Interventions: PrP-siRNA; Drug
Lead sponsor: Broad Institute of MIT and Harvard; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 5
States / cities: Boston, Massachusetts • Rochester, Minnesota • New York, New York + 2 more

Conditions: Chronic Fatigue Syndrome
Interventions: Placebo, Sodium Oxybate; Drug
Lead sponsor: University of Medicine and Dentistry of New Jersey; Other
Eligibility: 21 Years to 65 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Newark, New Jersey

Conditions: Adrenal Gland Neoplasm, Hypertension, Bone Diseases, Metabolic, Cardiovascular Disease, Hyperinsulinemia
Interventions: Not listed
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 7 Years to 70 Years
Enrollment: 1,150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2026
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Chronic Low Back Pain, Hip Ostearthritis, Myofascial Pain Syndrome, Fibromyalgia, Depression, Maladaptive Coping, Lumbar Spinal Stenosis, Insomnia, Sacroiliac Joint Pain, Lateral Hip and Thigh Pain, Anxiety, Dementia, Recent Leg Length Discrepancy
Interventions: Patient-Centered Care, Imaging-Directed Care; Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 60 Years to 89 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 2
States / cities: Pittsburgh, Pennsylvania • Richmond, Virginia

Conditions: HIV Infections, HIV Seronegativity
Interventions: ALVAC-HIV (vCP205); Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Myelodysplastic Syndrome, Recurrent Myelodysplastic Syndrome, Refractory Myelodysplastic Syndrome
Interventions: Navitoclax, Venetoclax, Decitabine, Bone Marrow Biopsy, Biospecimen Collection, Laboratory Biomarker Analysis, Quality-of-Life Assessment; Biological · Drug · Procedure + 1 more
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Search by objective public record fields.

A Test of Behavioral Intervention for Women at High Risk for HIV Infection

Dual-sided Hypoglossal neRvE stimulAtion for the treatMent of Obstructive Sleep Apnea (DREAM)

Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer

DICER1-related Pleuropulmonary Blastoma Cancer Predisposition Syndrome: A Natural History Study

Evaluation of the Efficacy and Safety of THRV-1268 in Participants With Long QT Syndrome Type 2 (LQTS2) and Type 3 (LQTS3)

Mindfulness-Based Therapy for Interstitial Cystitis/Bladder Pain Syndrome

Evaluating Heterologous-Insert Prime-Boost HIV Vaccine Regimens in HIV-Uninfected Adults

Copper Histidine Therapy for Menkes Diseases

A 48 Week Observational Study of the Frequency of Symptomatic Herpes Virus I and II in HIV Infected Subjects

Supporting Weak Immune System During Autoimmune Therapy: Testing Panzyga to Prevent Infections

Multicenter Evaluation of Children and Young Adults With Genotype Positive Long QT Syndrome

Diet, Exercise, Niacin, and Fenofibrate to Reduce Heart Disease Risk Factors in Individuals With HIV Lipodystrophy or Dyslipidemia

Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant

Treatment Use of 3,4-Diaminopyridine

A Study Investigating the Safety, Recovery, and Pharmacodynamics of Multiple Oral Administrations of SNIPR001 in Healthy Subjects

LMB-2 Immunotoxin in Treating Young Patients With Relapsed or Refractory Leukemia or Lymphoma

Transplant-Related Mortality in Patients Undergoing a Peripheral Blood Stem Cell Transplantation or an Umbilical Cord Blood Transplantation

Phenotypic and Genetic Factors in Autism Spectrum Disorders

PrP-targeting siRNA Safety & Mechanism Study

Use of Xyrem to Improve Sleep in Chronic Fatigue Syndrome

Clinical and Molecular Characteristics of Primary Aldosteronism in Blacks

Making Better Lives: Patient-Focused Care for Low Back Pain (LBP)

Safety and Effectiveness of Administering an HIV Vaccine in the Groin Versus the Arm

Navitoclax in Relapsed or Refractory High-Risk Myelodysplastic Syndrome